Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 4/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429214 | 1.00 | ACHE (0.37) | ACHECYP19A1FKBP5CRBNCYP11B2 | |
| SCHEMBL29620683 | 0.94 | BCHE (0.35) | ACHECYP19A1CYP11B2BCHETBXAS1 | |
| SCHEMBL307955 | 0.94 | BCHE (0.35) | ACHECYP19A1CYP11B2BCHETBXAS1 | |
| SCHEMBL29550114 | 0.85 | — | — | |
| SCHEMBL157325 | 0.85 | — | — | |
| Carbamic Acid SCHEMBL16823528 | 0.84 | KDM4E (0.41) | CYP11B2BCHETBXAS1IDH1TDP1 | |
| Hydrochloric Acid SCHEMBL31159090 | 0.83 | ALDH1A1 (0.35) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL27985804 | 0.83 | ALDH1A1 (0.35) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL29651204 | 0.83 | ALDH1A1 (0.35) | ACHEBCHE | |
| SCHEMBL28659623 | 0.77 | CYP19A1 (0.32) | ACHECYP19A1TBXAS1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703692-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. | 2024-12-03 | — | — | US | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3798220-B1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | SHANGHAI ZHIMENG BIOPHARMA INC. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-110511220-B | P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine | 上海挚盟医药科技有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| WO-2013052355-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2557082-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | Shionogi & Co., Ltd. (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| EP-0804440-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-5719278-A | TREATING EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157726-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | ACHE 1212/4885CYP19A1 2570/4885FKBP5 2319/4885 |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | COMT, EZH1, SETD7 | ACHE 680/4885CYP19A1 1989/4885FKBP5 4852/4885 |
| US-20220227721-A1 | P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF | KCNJ2, KCNN2, KCNH2 | ACHE 1212/4885CYP19A1 2570/4885FKBP5 2319/4885 |
| US-11365181-B2 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | KCNJ2, KCNN2, KCNH2 | ACHE 1203/4885CYP19A1 2560/4885FKBP5 2329/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | ACHE 157/4885CYP19A1 2812/4885FKBP5 1894/4885 |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | ACHE 321/4885CYP19A1 674/4885FKBP5 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.